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Docetaxel (Taxotere, TXT) is a semisynthetic taxoid obtained by
the chemical modification of a non-cytotoxic terpenoid containing
the taxane nucleus extracted from the needles of Taxus baccata
(Lavelle and Fizames 1989). Preclinical results have revealed a
very broad spectrum of antitumour activity against breast, lung,
pancreas, ovarian, colon, head and neck carcinomas (Bissery et al,
1995). Clinical results showed high single agent activity against
anthracycline refractory breast cancer but also against a variety of
other tumours including small cell lung cancer, ovarian, gastric
and head and neck carcinomas (Van Oosterom and Schrijvers
1995). Docetaxel, as well as the other taxanes, acts by stabilizing
microtubules to levels incompatible with normal metabolism. b-
tubulins are the targets for the drugs (Combeau et al, 1994) and
previous works have indicated that several b-tubulin isoforms
show an overexpression in cell lines resistant to taxol (Haber et al,
1995; Jaffrézou et al, 1995).
We have recently used two pancreatic murine tumours (P03 and
P02) as models to study possible determinants of docetaxel sensi-
tivity in vivo. Docetaxel was highly active in vivo against
advanced stage pancreatic ductal adenocarcinoma P03 and inac-
tive against early stage P02 (Bissery et al, 1991; Veitia et al, 1998).
We showed that the sensitive tumour P03 expresses a higher level
of Tau proteins when compared to the docetaxel refractory
neoplasm P02 (Veitia et al, 1998). This higher quantity of Tau may
increase the sensitivity to the drug since both Tau and docetaxel
stabilize microtubules. In this report we concentrate on MAP2
since we have shown that tumours P02 and P03 express the corre-
sponding mRNA and that MAP2-related peptides are recognized
by antibodies directed against the brain MAP2 protein (Veitia et al,
1998). In addition, it has been shown that proteolysis of MAP2
alters its interaction with tubulin and promotes tubulin aggregation
into anomalous structures in the presence of vinblastine (Fellous 
et al, 1994). We decided to study the effect of cathepsin D-proteo-
lysed MAP2 on microtubule formation in vitro, in the presence of
docetaxel. Cathepsin D was chosen as model protease because its
proteolysis pattern is similar to the one produced by tumour (P02
and P03) extracts. In addition, immunological evidence of its pres-
ence in these neoplasms was obtained. This type of in vitro
approach may provide insights of the contribution of MAP2 prote-
olysis to the modulation of the malignant cell response to the drug.
MATERIAL AND METHODS
Tumour models and mice
Docetaxel was previously evaluated for its antitumour activity in
vivo against murine pancreatic ductal adenocarcinomas P03 and
P02 and was found highly active against P03 and inactive against
P02. The tumours were maintained subcutaneously by serial
passages in the mouse strain of origin (C57BI/6) obtained at IFFA
CREDO (L’Arbresle, France) from strains obtained from the
Jackson Laboratories (Bar Harbor, ME, USA), when needed the
tumours were removed and frozen. Tumours are in the National
Cancer Institute repository (Frederick, MD, USA).
Antibodies
Anti a- and b-tubulin are two monoclonals antibodies (N356 and
N357) obtained from Amersham (Arlington Heights, IL, USA).
Anti-MAP2 152 is a monoclonal produced in our laboratory 
(Kalil et al, 1988; Veitia et al, 1998). The anti-mouse biotynilated
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Summary We have studied the state of microtubule associated protein 2 (MAP2) in the pancreatic ductal adenocarcinomas P03 and P02
(sensitive and refractory to docetaxel respectively) since they express the corresponding mRNA and MAP2-related peptides.
Immunohistochemical localization showed that in tumour P03 the MAP2-related peptides are highly expressed and confined to the epithelial
malignant cells while in P02 the intensity of the immunostaining is lower. However, anti a-tubulin staining followed a similar pattern suggesting
that the net amount of macromolecular structures in the sensitive tumour is higher than in the refractory one. This may explain its higher
sensitivity to docetaxel, because tubulin assembled into microtubules is the target of the drug. We found that protein extracts from both
tumours differed in their proteolytic activity on rat brain MAP2. Since the proteolysis pattern obtained was similar to the one produced by
Cathepsin D, we studied the effect of MAP2 proteolysed by this enzyme on microtubule formation in vitro. Proteolysis was found to increase
the tendency of tubulin to assemble into macromolecular structures (microtubules and aggregates) in the presence of docetaxel. This
suggests that in vivo proteolysis of MAP2 might increase microtubule alterations and potentiate the antitumour effect of docetaxel. © 2000
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binding domain polyclonal antibodies were prepared against 
a synthetic peptide chosen in a region of homology between the 
tubulin binding domains (TBD) of MAP2 and Tau
(VTSKIGSLENIKHVPGGG). The peptide was synthesized on a
column containing multiple lysine residues. No coupling to a
carrier protein was required before immunization. Immunization
schedule was as follows: a first subcutaneous injection (2 mg
peptide in complete Freund adjuvant) then a second and third
intramuscular (IM) injections (1 mg peptide in incomplete Freund
adjuvant) on days 10 and 21 respectively. Two additional IM injec-
tions were performed on days 36 and 50 (1 mg peptide, incomplete
adjuvant). Two antibodies (Prom A and M) reacting differently
against the MAP2 fragments containing the TBD were obtained
(See Results and Discussion).
Immunohistochemistry
Paraffin-embedded pancreatic tumours were deparaffined by a
xylene-ethanol-water treatment. Endogenous peroxidase activity
was inhibited with hydrogen peroxide and nonspecific antibody
binding sites were blocked with fetal calf serum. Slices were incu-
bated with anti a-tubulin or anti-MAP2-152 monoclonal antibodies
(diluted 1/2000 and 1/500 respectively) overnight at 4°C, and then
incubated with an antimouse biotinylated antibody and a complex
streptavidin-peroxidase. Detection was carried out using
aminoethylcarbazole (AEC, Sigma). Sections were counterstained
with haematoxylin, dehydrated and mounted. Images were acquired
by a Tri-CDD device (LH750RC3, Lhesa Rungis, France).
Western blot analysis of pancreatic tumours
Western blots were carried out as described by Veitia et al (1998)
using the following antibodies: anti a-tubulin (Sigma), anti
MAP2-152, polyclonal anti-Cathepsin D (DAKO) and the two
polyclonals anti-TBD PromA and Prom M.
In vitro MAP2 proteolysis
MAP2 was prepared from 9-day-old rat brains as described by
Fellous et al (1977). Proteolysis was induced by either extracts
from tumours or cathepsin D. The extracts were prepared by
homogenizing 1 g of tumour tissue in 5 ml of 10 mM phosphate
buffer pH 5.8. The suspension obtained was sonicated for 30 s and
clarified by centrifugation (100 000 g for 30 min). Proteolysis was
carried out at 37°C in the same phosphate buffer using either 1.5 U
of cathepsin D or 190 mg of total protein of tumour extract on 
80 mg of MAP2. The reaction was stopped at different times 
(0–60 min) by adding 1/10 volume of 10´ microtubule polymer-
ization buffer pH = 6.8 (1 M MES, 10 mM mM EGTA, 1 mM
EDTA, 10 mM MgCl2, 10 mM GTP, 10 mM b-mercaptoethanol).
This changes the nature of the buffer and corrects the pH to 6.4,
necessary for polymerization.
Microtubule assembly in the presence of docetaxel.
Measurement of turbidity, immunoblot analysis and
electron microscopy
Rat brain tubulin prepared as described by Weingarten et al (1975)
dialysed against polymerization buffer (1´) and proteolysed
MAP2 were mixed in ice-cooled spectrophotometer cells (1 mg
Tubulin/0.2 mg MAP2). Small aliquots of a docetaxel solution
(0.1 mM) were added with energic stirring to the cold mixture to
attain 1 or 4 mM final concentration. Cells were then tranferred to
a thermostated UVICON spectrophotometer and turbidity change
(OD350 nm) at 37°C was measured for 15 min. Then, the reaction
mixture was centrifuged at 12000 rpm for 20 min. Pellets and
supernatants were kept for further analyses.
Pellets (depolymerized in 100 ml of polymerization buffer on
ice) and supernatants of the experiments described above were
electrophoresed in 10% PAGE-SDS gels (NOVEX, San Diego,
CA) and transferred onto nitrocellulose membranes following 
the manufacturer’s instructions (NOVEX). Immunoblots were
performed with the MAP2 monoclonal antibody 152 produced in
our laboratory (Kalil et al, 1988), the two polyclonal antibodies
recognizing the tubulin binding domain of MAP2 and an anti-
b-tubulin. Detection was carried out by Enhanced
Chemiluminescence (ECL, Boehringer, Mannheim, Germany).
Small aliquots of the reaction mixtures described above (after
polymerization) were also analysed by transmission electron
microscopy as describe previously (Fromes et al, 1996).
RESULTS
Immunolocalization of polypeptides related to MAP2 in
P03 and P02 tumours. Western blot analysis
Immunohistochemistry using the anti-MAP2 monoclonal antibody
152 showed the expression of polypeptides related to this protein
in both pancreatic adenocarcinomas (Figure 1). In the docetaxel
sensitive tumour (P03) the peptides recognized by the antibody
were highly expressed and confined to the epithelial malignant
cells (Figure 1C). In contrast, in the refractory tumour P02 the
intensity of the immunostaining of the epithelial cells was lower
(Figure 1D). However, anti-MAP2 and anti a-tubulin staining
(Figure 1A,B) were reproducibly correlated suggesting that the net
amount of macromolecular structures (presumably microtubules)
in the refractory tumour is lower than in the sensitive one.
As reported previously (Veitia et al, 1998), the amount of the
MAP2-related peptides detected by Western blot is different in P03
and P02 tumour extracts. The MAP2 with a similar weight to brain
MAP2A and B was not detectable probably because of an intense
proteolytic activity of the tumours (Figure 2). Notably, P03
showed a greater amount of a polypeptide of 36–38 kDa, that we
had previously thought to contain the TBD (Veitia et al, 1998).
Interestingly, Figure 2 shows that a 36–38 kDa fragment was
recognized not only by the 152 monoclonal antibody recognizing
specifically brain MAP2 but also by one of the anti-TBD anti-
bodies (Prom A).
In vitro proteolysis of rat brain MAP2 induced by
tumour extracts or cathepsin D
Figure 3 shows that HMW rat brain MAP2 can be readily proteo-
lysed by tumour extracts. However, for equal amounts of protein
the P03 extract seemed to have higher proteolytic activity. In both
cases rat brain MAP2 was fully fragmented within the first 15 min
of reaction. In P03, a product of 75 kDa, observed at 15 min,
disappeared when reaction proceeded for a further 15 min.
However, this band remained virtually unchanged in the reaction
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a difference in the nature or amount of the proteases active against
rat brain MAP2 between the tumours.
Western blot analysis of tumour extracts showed the presence of
immunoreactive bands with molecular weights corresponding to
those expected for cathepsin D itself and its precursor (data not
shown). In addition, proteolysis induced by cathepsin D was
shown to generate an overall pattern very similar to those obtained
after treatment of MAP2 with tumour extracts suggesting that their
proteolytic activity may depend to a great extent on cathepsin D or
another protease close to it.
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Figure 1 Immunohistochemical analysis of the pancreatic tumours P03 and P02, sensitive and refractory to docetaxel respectively. Panels A and B: anti a-
tubulin staining (antibody dilution 1/2000). Panels C and D: anti-MAP2 staining (monoclonal 152, diluted 1/1000). Magnification 150´, insert magnification 600´
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Figure 2 Western blot of P03 and P02 tumour extracts. Immunodetection
was performed on symmetric blots using the anti-MAP2-152 (diluted 1/500)
and anti-TBD PromA antibodies (diluted 1/500). Each lane contained equal
amounts of a-tubulin. The arrow indicates the 36–38 kDa peptide recognized
by PromA antibody
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Figure 3 Proteolysis of rat brain MAP2 induced by P03 and P02 extracts
and by Cathepsin D. Eighty mg of MAP2 were treated with 190 mg of tumour
extract or 1.5 U of cathepsin D. The arrowhead indicates the 75 kDa
fragment mentioned in the text. The asterisk indicates »46 kDa fragment(s)
produced during proteolysisKinetic, Western blot and electron microscopy analyses
of tubulin assembly promoted by proteolysed MAP2
The kinetic analysis of tubulin assembly into macromolecular
structures using MAP2 with different degrees of proteolysis
induced by cathepsin D showed that in absence of docetaxel, the
turbidity for any given polymerization time decreased as the
protein MAP2 was proteolysed. For docetaxel concentrations 1
and 4 mM there was a clear increase in turbidity when proteolysis
time increased from 0 to 40 min (Figure 4). Microtubules from
each reaction condition were further studied by both Western blot
and electron microscopy.
Western blot analysis of the microtubule pellets with two
different antibodies directed against the MAP2/Tau TBD revealed,
before effective proteolysis took place, the 300 kDa band as well
as minor degradation products (Figure 5). Notice that PromA
recognizes poorly the 300 kDa protein in the pellets (faint bands in
presence of docetaxel). The intensity of all bands increased as a
function of the concentration of docetaxel in a dose-dependent
manner. At 20 min of proteolysis, the 300 kDa band almost disap-
peared and there was a large increase in the amount of degradation
fragments (mainly seen when docetaxel was present in the 
reaction medium). A major degradation product of about 46 kDa
accumulated in the polymer phase (microtubule pellet). From a
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Figure 5 Western blot analysis of the products obtained after tubulin assembly induced by MAP2 proteolysed for 0 to 40 min and in the presence of increasing
amounts of docetaxel (0–4 mM TXT). After incubation of MAP2 (proteolysed or not) and tubulin at 37°C during 15 min the mixtures were centrifuged for 15 min
at 12000 g, both the depolymerised pellets and the supernatants were analysed by Western blot (perfectly symmetric) with two different anti-tubulin binding
domain antibodies (PromA and B). The 300 kDa protein is indicated by an arrowhead
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Figure 4 Effect of MAP2 proteolysis on the kinetics of tubulin polymerization in presence of increasing amounts of docetaxel. One mg/ml of purified tubulin
was incubated with MAP2 (0.2 mg/ml) in different degradation states in the absence (solid lozenges) of docetaxel or in the presence of 
1 mM (empty squares) or 4 mM (empty triangles) of the drug. Panels A, B and C present the results for proteolysis times 0, 20 and 40 min respectivelyquantitative point of view, the Western blot results for the super-
natants were the reverse of those obtained for the pellets (Figure
5). Notice here that PromA antibody recognized better the 300
kDa MAP2 in the supernatant. The band recognized may represent
a different MAP2 isoform (conformation or post-translational
modification). The amount of b-tubulins in the pellets (mono-
clonal antibody N356) increased following the degree of MAP2
proteolysis even in absence of the drug, contrasting with the
results of the kinetic studies. This is probably due to the formation
of small aggregates that do not alter turbidity but precipitate
during centrifugation. The increase in the pellet of both tubulin
and some MAP2 fragments, mainly the 46 kDa polypeptide, in the
presence of docetaxel showed clearly that MAP2 proteolysis
enhanced the assembly of tubulin into macromolecular structures.
This observation was confirmed by electron microscopy analysis
of the microtubules obtained for each of the reaction conditions.
When MAP2 was proteolysed, microtubules were hardly polymer-
ized in the absence of the drug (Figure 6A), whereas at 4 mM
docetaxel, a considerable amount of microtubules (normal or
open) as well as a net increase in the number of aggregates (dark
structures) was noticed (Figure 6B).
DISCUSSION
Immunohistochemistry of tumours P03 and P02, sensitive and
refractory to docetaxel respectively, has shown that both MAP2
related polypeptides and a-tubulin are more abundant in the
docetaxel sensitive tumour. This reflects that the net amount of
macromolecular structures (presumably microtubules) in the
sensitive tumours is higher than in the refractory one. Since
docetaxel binds preferentially to tubulin subunits assembled into
microtubules rather than to tubulin dimers (Parness and Horwits,
1981), a higher density of the microtubule network in tumour P03
may explain its higher sensitivity to the drug. In addition, micro-
tubules in P03 could be intrinsically more stable than in P02
because for equal amounts of tubulin protein, greater amounts of
the microtubule-stabilizing Tau proteins are found in the P03
(Veitia et al, 1998). In addition to this, we decided to explore other
factors than microtubule density that may modulate microtubule
sensitivity to docetaxel.
Immunoblot analysis of tumour extracts using a monoclonal
anti MAP2 antibody has shown the presence of MAP2-related
peptides in both tumours P03 and P02. An increase in the amounts
of a 36–38 kDa product thought to contain the TBD has also been
noticed in the docetaxel sensitive P03 (Veitia et al, 1998).
Interestingly, the polyclonal anti-TBD (PromA) is able to recognize
a band of the same length in P03 extracts. This fragment is likely
to be a MAP2 degradation product. However, we cannot exclude
the possibility that it is a comigrating Tau fragment also containing
the TBD. To address this question immunoprecipitation was
unsuccessfully attempted. In any case, one may suppose that
MAP2 and Tau TBDs share not only structural but also functional
similarities.
The study of the proteolytic activity of tumour extracts (P03 and
P02) on purified rat brain MAP2, showed that both extracts were
able to degrade the MAP although P03 displayed a greater activity
(for equal amounts of total protein) (Figure 3). The kinetic analysis
of the influence of proteolysis induced by the extracts on the capa-
bility of MAP2 to promote tubulin assembly into macromolecular
structures was attempted. However, the presence of some compo-
nent in the extract produced anomalous results (lack of plateau for
the kinetic curves). Figure 3 shows that the degradation patterns
produced by the tumour extracts and by cathepsin D are very close.
In addition, anti-cathepsin D immunoreactive polypeptides were
found in both tumours (P02 and P03). Therefore, cathepsin D was
chosen as a model protease to further study the effect of docetaxel
on microtubule assembly promoted by proteolysed MAP2.
The kinetic monitoring of tubulin polymerization shows that in
the absence of docetaxel, the ability of MAP2 to induce micro-
tubule formation is impaired as it is proteolysed by cathepsin D
(Figure 4). Addition of the drug causes a notable increase in
turbidity even when the MAP is proteolysed, suggesting that
tubulin polymers are produced. Interestingly, this increase in OD
is more important as MAP2 is degraded suggesting that, in addi-
tion to microtubule polymerization, a concomitant aggregation
process induced by the drug is also taking place. Electron
microscopy has shown that it is indeed the case (Figure 6). It is
worth noting that although information concerning intracellular
concentrations of docetaxel is scarce (Lavelle et al, 1995), rough
calculations suggest that 1–4 mM (as used in our study) can be
relevant at least in cultured cells.
Western blots from the kinetic experiments show that either
the whole MAP or its proteolytic products including the 46 kDa
fragment can promote tubulin polymerization and/or aggregation
and suggest that docetaxel enhances the recruitment of MAP2
fragments which have an impaired ability to induce tubulin
assembly into macromolecular structures. Interestingly, the anti-
TBD antibody PromM recognizes very well the HMW fragments
of MAP2 while PromA is less effective in doing so. This
suggests that, MAP2 being a very huge protein, the PromA
epitope can be masked by another portion of the protein even
under mild denaturing conditions. These data suggest that MAP2
proteolysis induces conformational changes in the protein
around the TBD. A possible interaction between the MAP2
projection arm and the TBD that could affect the conformation or
accessibility of the latter. The conformational changes involving
the TBD might favour binding to tubulin in a metastable way
which would then be stabilized by the drug. However, some of
the TBD-containing fragments may be impaired to promote effi-
cient microtubule polymerization and would still induce tubulin
aggregation. The latter process should be enhanced by the pres-
ence of docetaxel. Alternatively, changes in tubulin upon binding
of MAP2 may depend on the nature of the proteolytic fragment.
In this case, the complexes tubulin-MAP2 may have different
affinities for docetaxel or may more or less easily produce
abnormal structures.
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Figure 6 Electron microscopic analysis of the tubulin polymerization
products induced by MAP2 proteolysed for 20 min either in the absence (left
panel) or in the presence (right panel) of docetaxel (4 mM)MAP2 proteolysis and in vivo sensitivity to docetaxel 549
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Proteolysis of MAP2 may take place in a poorly controlled way
in the neoplastic cells and may induce changes in MAP2 confor-
mation. These changes may increase sensitivity of the tumour to
docetaxel either by increasing the density of the microtubule
network and/or the amount of abnormal tubulin polymers. This
mechanism was suggested to explain the higher sensitivity of
MAP2 microtubules to vinblastine and other microtubule agents
(Fellous et al, 1994). The identification of other neoplastic
proteases that are able to degrade MAP2 in tumours P02 and P03
has to be explored. We suggest that cathepsin D-like proteases and
cathepsin D itself may degrade MAP2 in vivo and contribute to
modulate tumour response to docetaxel.
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